Background
Methods
Study design and setting
Participants
Clinical evaluation
Measurements
Allodynia symptom checklist
Numeric rating scale
Headache impact test
Self-rating depression scale
Statistical analysis
Results
Migraineurs n = 176 | Controls n = 132 |
p value | |
---|---|---|---|
Positive TP count | 6.3 ± 4.3 | 1.7 ± 2.4 |
p < 0.001u
|
Migraineurs n = 176 |
p value | Controls n = 132 |
p value | |||
---|---|---|---|---|---|---|
Gender | Female (n = 148) | Male (n = 26) | Female (n = 111) | Male (n = 21) | ||
Positive TP count | 6.6 ± 4.4 | 4.4 ± 3.4 | 0.012u
| 1.8 ± 2.5 | 0.8 ± 1.9 | 0.028u
|
Migraine without IWH | Migraine with IWH |
p value | Migraine without ACA | Migraine with ACA |
p value | |
---|---|---|---|---|---|---|
n = 102 |
n = 74 |
n = 61 |
n = 115 | |||
Variables | ||||||
General variables | ||||||
Female gender | 80 (78.4%) | 68 (91.9%) |
0.027
x
| 45 (73.8%) | 103 (89.6%) |
0.012
x
|
Age (years) | 39.9 ± 9.7 | 37.4 ± 10.6 | 0.106t
| 39.4 ± 11.0 | 38.5 ± 9.7 | 0.595t
|
Migraine-specific variables | ||||||
Migraine type | 0.703x
|
0.038
x
| ||||
Migraine without aura | 62 (60.8%) | 42 (56.8%) | 43 (70.5%) | 61 (53.0%) | ||
Migraine with aura | 40 (39.2%) | 32 (43.2%) | 18 (29.5%) | 54 (47.0%) | ||
Age at migraine onset (years) | ||||||
less than 15 | 18 (17.6%) | 22 (29.7%) |
0.043
x
| 13 (21.3%) | 27 (23.5%) |
0.032
x
|
15-19 | 26 (25.5%) | 20 (27.0%) | 9 (14.8%) | 37 (32.2%) | ||
20-24 | 17 (16.7%) | 12 (16.2%) | 9 (14.8%) | 20 (17.4%) | ||
25-29 | 7 (6.9%) | 9 (12.2%) | 8 (13.1%) | 8 (7.0%) | ||
30 or more | 34 (33.3%) | 11 (14.9%) | 22 (36.1%) | 23 (20.0%) | ||
Migraine duration (years) | ||||||
less than10 | 27 (26.5%) | 15 (20.3%) | 0.351x
| 22 (36.1%) | 20 (17.4%) |
0.027
x
|
10-19 | 35 (34.3%) | 33 (44.6%) | 18 (29.5%) | 50 (43.5%) | ||
20-29 | 27 (26.5%) | 14 (18.9%) | 15 (24.6%) | 26 (22.6%) | ||
30 or more | 13 (12.7%) | 12 (16.2%) | 6 (9.8%) | 19 (16.5%) | ||
Duration of headache attack (hours) | 0.884x
| 0.456x
| ||||
12 or less | 46 (45.1%) | 35 (47.3%) | 30 (49.2%) | 51 (44.3%) | ||
13-24 | 40 (39.2%) | 25 (33.8%) | 24 (39.3%) | 41 (35.7%) | ||
25-48 | 9 (8.8%) | 8 (10.8%) | 3 (4.9%) | 14 (12.2%) | ||
more than 48 | 7 (6.9%) | 6 (8.1%) | 4 (6.6%) | 9 (7.8%) | ||
Frequency of headache (no/year) |
0.005
x
|
0.011
x
| ||||
1-6 | 23 (22.5%) | 6 (8.1%) | 16 (26.2%) | 13 (11.3%) | ||
7-12 | 20 (19.6%) | 11 (14.9%) | 11 (18.0%) | 20 (17.4%) | ||
13-54 | 51 (50.0%) | 40 (54.1%) | 31 (50.8%) | 60 (52.2%) | ||
more than 54 | 8 (7.8%) | 17 (23.0%) | 3 (4.9%) | 22 (19.1%) | ||
Headache intensity | 0.621f
| 0.486f
| ||||
Mild | 4 (3.9%) | 1 (1.4%) | 2 (3.3%) | 3 (2.6%) | ||
Moderate | 40 (39.2%) | 28 (37.8%) | 27 (44.3%) | 41 (35.7%) | ||
Severe | 58 (56.9%) | 45 (60.8%) | 32 (52.5%) | 71 (61.7%) | ||
Headache disability (HIT-6) | 0.056x
|
0.004
x
| ||||
severe (60 or more) | 56 (54.9%) | 52 (70.3%) | 28 (5.9%) | 80 (69.6%) | ||
Acute cutaneous allodynia (yes) | 59 (57.8%) | 56 (75.7%) |
0.022
x
| – | – | |
Interictal WPH (yes) | – | – | 18 (29.5%) | 56 (48.7%) |
0.022
x
| |
Migraine-associated symptoms | ||||||
Nausea/Vomiting | 96 (94.1%) | 69 (93.2%) | 1f
| 58 (95.1%) | 107 (93.0%) | 0.75 f
|
Photophobia | 76 (74.5%) | 62 (83.8%) | 0.197x
| 37 (60.7%) | 101 (87.8%) |
<0.001
x
|
Phonophobia | 62 (60.8%) | 56 (75.7%) | 0.056x
| 27 (44.3%) | 91 (79.1%) |
<0.001
x
|
Osmophobia | 44 (43.1%) | 37 (50.0%) | 0.454x
| 21 (34.4%) | 60 (52.2%) |
0.037
x
|
Depression (SDS48 or more) | 15 (14.7%) | 23 (31.1%) |
0.016
x
| 10 (16.4%) | 28 (24.3%) | 0.304x
|
Use of medication | ||||||
Use of acute medication | 14 (13.7%) | 13 (17.6%) | 0.627x
| 9 (14.8%) | 18 (15.7%) | 1x
|
Use of a triptan | 45 (44.1%) | 33 (44.6%) | 1x
| 22 (36.1%) | 56 (48.7%) | 0.148x
|
Use of prophylactic drugs | 6 (5.9%) | 11 (14.9%) | 0.083x
| 4 (6.6%) | 13 (11.3%) | 0.455x
|
Variable | Odds ratio | 95% IC |
P
| |
---|---|---|---|---|
Gender (female versus male) | 3.47 | 1.17-10.3 | 0.025 | |
Age at onset migraine (year) | ||||
15-19 vs. less than 15 | 0.56 | 0.23-1.38 | 0.3 | |
20-24 vs. less than 15 | 0.59 | 0.22-1.62 | 0.31 | |
25-29 vs. less than 15 | 1.38 | 0.38-4.98 | 0.63 | |
30 or more vs. less than 15 | 0.242 | 0.09-0.66 | 0.005 | |
Migraine frequency (attacks per year) | ||||
7-12 vs. 1-6 | 1.58 | 0.46-5.48 | 0.47 | |
13-54 vs. 1-6 | 2.06 | 0.72- 5.89 | 0.18 | |
more than 54 vs. 1-6 | 8.75 | 2.34-32.7 | 0.001 |
Discussions
Prevalence and distribution of positive TP in migraines and healthy controls
Evaluation of positive TP site as the reduced pressure pain threshold (PPT) site
Descending order of prevalence of positive TP of our controls
n = 132 | Ascending order of PPT of controls of Marques et al. [38]
n = 54 | Ascending order of PPT of controls of Tastekin et al. [39]
n = 50 |
---|---|---|
Second Rib | Second Rib | Occiput |
Low Cervical | Low Cervical | Low Cervical |
Trapezius | Occiput | Second Rib |
Lateral Epicondyle | Lateral Epicondyle | Knee |
Occiput | Trapezius | Trapezius |
Greater Trochanter | Knee | Lateral Epicondyle |
Supraspinatus | Supraspinatus | Supraspinatus |
Gluteal | Gluteal | Greater Trochanter |
Knee | Greater Trochanter | Gluteal |
Prevalence of positive TP
Correlation between the prevalence of positive TP of migraineurs and PPT of corresponding sites in FM patients
Factors underlying differences in positive TP on sites
Similarity between the sites with high prevalence of positive TP in migraineurs and reduced PPT sites of FM patients
Descending order of prevalence of positive TP of our migraineurs n = 132 | Ascending order of PPT of FM patients of Marques et al. n = 54 | Ascending order of PPT of FM patients of Tastekin et al. n = 50 |
---|---|---|
Low Cervical | Second Rib | Second Rib |
Second Rib | Low Cervical | Low Cervical |
Lateral Epicondyle | Lateral Epicondyle | Occiput |
Trapezius | Occiput | Lateral Epicondyle |
Occiput | Supraspinatus | Knee |
Supraspinatus | Knee | Trapezius |
Gluteal | Trapezius | Supraspinatus |
Knee | Gluteal | Greater Trochanter |
Greater Trochanter | Greater Trochanter | Gluteal |